Search
Search Results
-
Real-world data on neoadjuvant chemotherapy with dual-anti HER2 therapy in HER2 positive breast cancer
BackgroundNeoadjuvant chemotherapy with dual-targeted therapy is the standard treatment for human epidermal growth factor 2 (HER2)-positive breast...
-
Prognostic impact of HER2-low positivity in patients with HR-positive, HER2-negative, node-positive early breast cancer
Adjuvant therapy for patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, node-positive, early...
-
Treatment of HER2-positive cutaneous apocrine carcinoma of the axilla
Cutaneous apocrine carcinoma (CAC) is an extremely rare skin appendage malignant tumor that develops in the apocrine sweat glands, and no...
-
HER2-positive invasive lobular carcinoma: a rare breast cancer which may not necessarily require anti-HER2 therapy. A population-based study
BackgroundHER2-positive (HER2 +) invasive lobular breast cancer (ILC) is rare and poorly characterised. In particular, patient outcomes compared to...
-
Comparative Activity of Chlonisol and Temozolomide in Mice After Intracranial Transplantation of Ehrlich Carcinoma and HER2-Positive Breast Cancer
In continuation of a preclinical study of the new alkylating anticancer drug chlonisol {2-[3-(2-chloroethyl)-3-nitrosoureido]-1,3-propanediol}...
-
Differential response of HER2-positive breast cancer to anti-HER2 therapy based on HER2 protein expression level
BackgroundIncreasing data indicate that HER2-positive (HER2 + ) breast cancer (BC) subtypes exhibit differential responses to targeted anti-HER2...
-
High-grade HER2-positive mucoepidermoid carcinoma of the breast: a case report and review of the literature
BackgroundMucoepidermoid carcinoma of the breast is a rare special type of salivary gland-like tumor of the breast, usually displaying...
-
Innovative Therapeutic Approaches for Patients with HER2-Positive Breast Cancer
Overexpression of human epidermal growth factor receptor 2 (HER2), a transmembrane tyrosine kinase receptor, has been described in about 15–20% of...
-
SIRT6 promotes metastasis and relapse in HER2-positive breast cancer
The histone deacetylase sirtuin 6 (SIRT6) has been endowed with anti-cancer capabilities in many tumor types. Here, we investigate the impact of...
-
HER2 amplification by next-generation sequencing to identify HER2-positive invasive breast cancer with negative HER2 immunohistochemistry
BackgroundHuman epidermal growth factor receptor 2 (HER2 ) positive breast carcinomas due to HER2 amplification are associated with aggressive...
-
Pathologic complete response of ductal carcinoma in situ to neoadjuvant systemic therapy in HER2-positive invasive breast cancer patients: a nationwide analysis
PurposeDuctal carcinoma in situ (DCIS) is present in more than half of HER2-positive invasive breast cancer (IBC). Recent studies show that DCIS...
-
Imaging of HER2 detected receptor expression positive breast cancer: from detection to interpretation
BackgroundAggressive invasion, high recurrence rate, and poor prognosis are common features of the human epidermal growth factor receptor-2...
-
HER2 amplification level by in situ hybridization predicts survival outcome in advanced HER2-positive breast cancer treated with pertuzumab, trastuzumab, and docetaxel regardless of HER2 IHC results
BackgroundThe role of HER2 amplification level in predicting the effectiveness of HER2-directed therapies has been established. However, its...
-
Molecular classification of hormone receptor-positive HER2-negative breast cancer
Hormone receptor-positive (HR + )/human epidermal growth factor receptor 2-negative (HER2 − ) breast cancer is the most prevalent type of breast cancer,...
-
Neratinib for HER2-positive breast cancer with an overlooked option
Positive human epidermal growth factor receptor 2 (HER2) expression is associated with an increased risk of metastases especially those to the brain...
-
Cuproptosis-related genes predict prognosis and trastuzumab therapeutic response in HER2-positive breast cancer
Breast cancer is the most common diagnosed cancer, the HER2-positive subtype account for 15% of all breast cancer. HER2-targeted therapy is the...
-
Pyrotinib and chrysin synergistically potentiate autophagy in HER2-positive breast cancer
Human epidermal growth factor receptor 2 (HER2)-positive breast cancer (BC) has been the most challenging subtype of BC, consisting of 20% of BC with...
-
Phosphorylation of EZH2 differs HER2-positive breast cancer invasiveness in a site-specific manner
HER2-positive breast cancer (BC) invasiveness and drug-resistance issue is the critical treatment obstacle recently. We investigated the total and...
-
Diffusion-weighted imaging in addition to contrast-enhanced MRI in identifying complete response in HER2-positive breast cancer
ObjectivesThe aim of this study is to investigate the added value of diffusion-weighted imaging (DWI) to dynamic-contrast enhanced (DCE)-MRI to...
-
Efficacy of Lapatinib Plus Capecitabine After TDM-1 in HER2-Positive Metastatic Breast Cancer Patients
Different targeted therapy options exist for treating HER2-positive metastatic breast cancer patients. This study evaluated the efficacy and...
